Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.69 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.56 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.42 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3731699 | 0.86 | HRH3 (0.88) | HRH3KCNH2GPR119CCR5MGLL | |
| SCHEMBL3670891 | 0.85 | HRH3 (0.88) | HRH3KCNH2GPR119CCR5 | |
| SCHEMBL3726028 | 0.85 | HRH3 (0.88) | HRH3KCNH2GPR119CCR5 | |
| SCHEMBL18924338 | 0.85 | HRH3 (0.70) | HRH3KCNH2GPR119CCR5USP30 | |
| SCHEMBL3636321 | 0.85 | HRH3 (0.65) | HRH3KCNH2GPR119CCR5MGLL | |
| Hydrochloric Acid SCHEMBL3639931 | 0.84 | HRH3 (0.64) | HRH3KCNH2GPR119CCR5MGLL | |
| SCHEMBL3731656 | 0.82 | HRH3 (1.00) | HRH3KCNH2GPR119CCR5USP30 | |
| SCHEMBL3636580 | 0.82 | GPR119 (0.83) | HRH3KCNH2GPR119USP30 | |
| SCHEMBL4944133 | 0.81 | HRH3 (1.00) | HRH3KCNH2GPR119 | |
| SCHEMBL3727978 | 0.81 | HRH3 (1.00) | HRH3KCNH2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | WYETH (US) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293771-A1 | AZACYCLYLBENZAMIDE DERIVATIVES AS HISTAMINE-3 ANTAGONISTS | HRH4, HRH3, HRH2 | HRH3 2/4885KCNH2 581/4885GPR119 655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.